Biocon Q4 PAT may dip 192.8% YoY to Rs 67.1 cr: ICICI Securities

ICICI Securities has come out with its fourth quarter (January - March’ 24) earnings estimates for the PHARMA sector. The brokerage house expects Biocon to report net profit at Rs 67.1 crore down 192.8% year-on-year (down 78.7% quarter-on-quarter).

Net Sales are expected to increase by 3.5 percent Y-o-Y (down 1.2 percent Q-o-Q) to Rs 3,730.4 crore, according to ICICI Securities.

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise/fall by 8 percent Y-o-Y (down 37.5 percent Q-o-Q) to Rs 623 crore.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.